Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have been positive for serum anti-human T-cell lymphotropic virus type I antibody~* Subjects with hematologically or pathohistologically confirmed as peripheral lymphoid tumor which surface antigen analysis has identified to be of T-cell origin~* Subjects who have been classified into acute subtype, the lymphoma subtype or chronic subtype with poor prognostic factors~* Subjects who have been positive for CCR4 by CCR4 expression analysis~* Subjects who have never been treated for adult T-cell leukemia-lymphoma~* Subjects who have presented enlarged lymph nodes, tumor nodules in extranodal organs, abnormal lymphocytes in peripheral blood or cutaneous lesions~* Subjects with a performance status of 0 to 2~* Subjects who have been negative for HBs antigen and anti-HCV antibody~* Subjects who have given written voluntary informed consent to participate in the study~Exclusion Criteria:~* Subjects who are scheduled for transplant therapy such as hematopoietic stem-cell transplantation~* Subjects who had myocardial infarction within 12 months before study enrollment or who have cardiac disease that may worsen during treatment with doxorubicin~* Subjects who have been positive for anti-HIV antibody~* Subjects with active multiple cancer~* Subjects with a history of allergic reactions to therapeutic antibodies~* Subjects who require emergency radiotherapy for treating the symptoms caused by bulky masses or who may require such radiotherapy after the start of the study~* Subjects who are pregnant, lactating or of childbearing potential, or who are planning to have children

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mLSG15 (Type: ACTIVE_COMPARATOR): None
- mLSG15 + KW-0761 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).